Market Overview

Exelis Announces Cabozantinib Phase 2 Data Demonstrate Encouraging Clinical Activity


Exelixis, Inc. (NASDAQ: EXEL) today reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial.

The data support the findings that cabozantinib reduces or stabilizes metastatic bone lesions in nearly all patients evaluable by bone scan, reduces bone pain and narcotic analgesic medication and results in an increase in hemoglobin in patients with anemia. The data also suggest that cabozantinib shows an encouraging early signal of durable clinical benefit in both docetaxel-naïve and pretreated patients.

Posted-In: News FDA


Related Articles (EXEL)

View Comments and Join the Discussion!